• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bjerkholt Eric bought $49,600 worth of shares (2,000 units at $24.80), increasing direct ownership by 17% to 14,000 units (SEC Form 4)

    3/27/24 8:47:19 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BJERKHOLT ERIC

    (Last) (First) (Middle)
    C/O MIRUM PHARMACEUTICALS, INC.
    950 TOWER LANE, SUITE 1050

    (Street)
    FOSTER CITY CA 94404

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mirum Pharmaceuticals, Inc. [ MIRM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/27/2024 P 2,000 A $24.8 14,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Judit Ryvkin, Attorney-in-Fact 03/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MIRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    5/19/2025$73.00Buy
    H.C. Wainwright
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    9/20/2023$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $MIRM
    Financials

    Live finance-specific insights

    See more
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      - 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

      2/26/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

      - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

      1/13/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GLOBAL CONTROLLER Howe Jolanda sold $107,343 worth of shares (2,415 units at $44.45), decreasing direct ownership by 50% to 2,426 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/19/25 5:40:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GLOBAL CONTROLLER Howe Jolanda exercised 58,215 shares at a strike of $2.67 and sold $2,554,763 worth of shares (57,606 units at $44.35), increasing direct ownership by 14% to 4,841 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND COO Radovich Peter converted options into 14,440 shares and sold $348,364 worth of shares (7,879 units at $44.21), increasing direct ownership by 54% to 18,672 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:07 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/15/25 3:32:46 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/14/25 11:59:51 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.

      10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

      5/7/25 4:08:12 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 5:04:31 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/12/25 4:51:20 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/10/25 5:12:58 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednesday, May 21st at 9:00 AM ET. Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. is a biopharmaceutical compan

      5/14/25 4:05:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $44.27 per share, Mirum's closing trading price on May 9, 2025, and will vest over four years, with 25%

      5/9/25 6:00:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00

      5/19/25 8:53:13 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

      Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

      4/17/24 7:27:53 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously

      12/18/23 11:54:26 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

      For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

      2/21/25 11:48:20 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 4:37:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:55:40 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:25:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care